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Abstract
The past decade has seen remarkable progress in increasing access to antiretroviral therapy in resource-limited settings.
Early concerns about the cost and complexity of treatment were overcome thanks to the efforts of a global coalition of
health providers, activists, academics, and people living with HIV/AIDS, who argued that every effort must be made to
ensure access to essential care when millions of lives depended on it. The high cost of treatment was reduced through
advocacy to promote access to generic drugs; care provision was simplified through a public health approach to
treatment provision; the lack of human resources was overcome through task-shifting to support the provision of care
by non-physicians; and access was expanded through the development of models of care that could work at the
primary care level. The challenge for the next decade is to further increase access to treatment and support sustained
care for those on treatment, while at the same time ensuring that the package of care is continuously improved such
that all patients can benefit from the latest improvements in drug development, clinical science, and public health.
Introduction
Since 2001, the international effort to scale up antiretro-
viral therapy (ART) in the developing world has been one
of the most important programmes in global health [1].
Initially, there was considerable reluctance to provide
ART in developing countries, due to concerns that treat-
ment was too expensive, too complex, and that drug
resistance would be promoted by inadequate pro-
grammes [2]. In particular, it was argued that ART was
not cost-effective and that prevention interventions
should be prioritized [3].
Despite these concerns, treatment programmes began to
deliver ART at scale, and in less than a decade, more than
five million people were successfully started on treatment.
This remarkable progress was supported by a global coali-
tion of doctors, patients, civil society actors, governments,
and non-governmental organizations, who refused to
accept that millions of people could be consigned to an
early death from a disease that in developed countries had
been transformed into a chronic, manageable condition.
This article provides an overview of the main policy
and delivery challenges to the provision of effective ART
in resource-limited settings, before outlining some of the
future challenges for the coming years.
Global advocacy to reduce the cost of treatment
The early reluctance to support ART for developing
countries was driven by both public health caution and
treatment cost. The fact that antiretroviral medicines
were priced beyond the reach of most people who needed
them in Africa had long been an international concern: at
the International AIDS Conference in Stockholm in 1988
there was debate about how to ensure people in the
developing world could access the treatment of that time
- zidovudine monotherapy - which was marketed at a
price of US$8000 per year [4]. Triple therapy, available in
developed countries since late 1996, was considered far
too expensive for resource-limited settings, and UN
agencies [5], academics [3], and major donors alike [6] all
argued against providing treatment in favour of focusing
funding on prevention. As a consequence, many high-
prevalence countries were slow to adopt national treat-
ment plans.
Civil society groups, and in particular people living with
HIV/AIDS, were crucial to breaking the deadlock. Patient
groups in Thailand, Brazil, South Africa, India, Kenya,
Uganda, and other high-burden countries formed alliances
with health providers, non-governmental organizations,
and health groups in developed countries to argue the
case that the cost of treatment was too high [7]. Activist
demonstrations took place across the world from New
York to Bangkok to raise attention about the global
inequities in access to treatment [8]. * Correspondence: nathan.ford@msf.org
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scape. In South Africa, home to the largest number of
people living with HIV/AIDS, the government fought
(and arguably won) a court case against a consortium of
39 pharmaceutical companies over a law that would
allow the government to source more affordable antire-
trovirals from neighbouring countries [9].
Thailand and Brazil also played a critical part. Both
countries established public capacity to produce medicines
at a fraction of the price demanded by multinational phar-
maceutical companies. These two countries played a
leadership role by challenging the international monopo-
lies of antiretroviral drugs and producing generic versions
for a fraction of the price of the patented equivalents [10].
Widespread access to affordable antiretrovirals became
feasible after the announcement by an Indian generics
manufacturer in early 2001 that triple therapy could be
manufactured for less than a dollar a day. This established
a dynamic of global market competition that in 10 years
has brought down the price of standard triple therapy
from $US 10,000 per patient/year to almost $US50 [11].
Today, over 80% of ART used in low-income and middle-
income countries is purchased from Indian generics com-
panies [12]. The dramatic reduction in the cost of treat-
ment was essential to shifting the cost-effectiveness
equation, and from 2003 several international funding
streams were established to support ART scale up, notably
the Global Fund to Fight AIDS, Tuberculosis and Malaria
and the US President’s Emergency Plan for AIDS Relief
[1].
Overcoming the human resource crisis
As programmes began to enrol increasing numbers of
patients, it became clear that the lack of qualified health
personnel, particularly in Africa, would prove to be a
major bottleneck in increasing access to treatment [13].
Whereas in high-income countries HIV/AIDS has tradi-
tionally been managed by a range of specialists from der-
matology to oncology, health centres in sub-Saharan
Africa faced with a dominant proportion of the global
AIDS burden have a critical shortage of the most basic
essential health staff. High HIV-prevalence countries like
Malawi have 100 times fewer doctors per population than
the USA [14].
A simplified treatment paradigm was required in
resource-limited settings, entailing a shift from a specia-
lized medical approach to a public health approach, in
which the majority of clinical tasks would be undertaken
by lower health cadres such as nurses. Given the vast
numbers of lives being lost to HIV/AIDS every day, task-
shifting strategies were initially employed outside of a for-
mal evidence base. Rather than waiting for randomized
trial data to show that nurses could perform as well as
doctors in the prescribing of antiretrovirals, operational
research was conducted to assess the effectiveness of such
a strategy at the same time as it was being rolled out as
national policy. Countries such as Lesotho [15], South
Africa [16], and Malawi [17] demonstrated that with ade-
quate training and supervision, routine clinical manage-
ment of patients on ART could be delegated to nurses.
The effectiveness of task shifting was subsequently con-
firmed by randomized trials [18], and substantial program-
matic evidence has now accumulated around the benefits
of task shifting in terms of increased access to care and
improved team dynamics [19].
Simplifying drug regimens and monitoring
The delivery of ART at the primary care level required a
regimen that is easy to store, simple to take, and could be
administered by lesser-trained health cadres via standar-
dized guidelines. The development of fixed-dose combina-
tion ART was one answer to these requirements. World
Health Organization (WHO) guidelines for antiretroviral
therapy in resource-limited settings, first issued in 2001,
recommended a regimen of nevirapine, stavudine, and
lamivudine, as the preferred option [11]. This recommen-
dation provided crucial scientific and political support for
the use of a simple, affordable twice-daily regimen [20].
Implementation at large scale began in 2003, and by 2008,
access to antiretroviral drugs in low-income and middle-
income countries had risen tenfold [21] As well as provid-
ing guidance on drug regimens, the WHO guidelines also
addressed the need for simplified toxicity and efficacy
monitoring. The ability to perform CD4 counts and moni-
tor viral load and levels of various markers of toxicity,
although desirable, should not be a precondition to start-
ing treatment.
Decentralizing HIV/AIDS care to the primary care level
Task shifting and simplification strategies have been essen-
tial for supporting equitable access to care. Across sub-
Saharan Africa, doctors are in short supply and for the
most part are located in hospitals in cities: rural parts of
S o u t hA f r i c af o re x a m p l eh a v e1 4t i m e sf e w e rd o c t o r s
than the national average, whereas over half of Mozambi-
que’s doctors are working in the capital city, Maputo [14].
Because of this uneven distribution of clinical staff, policies
that insist on doctor-based provision of antiretroviral ther-
apy have been, by default, polices that limit access to treat-
ment for populations living in rural areas.
Because distance to health services is associated with
poorer adherence [22] and higher rates of defaulting from
care [23], the decentralization of antiretroviral care to
health centres in rural areas is critical for improving pro-
gramme outcomes. Thus, another important modification
to the standard model of HIV care practiced in high-
income settings was the adaptation of services such that
ART could be delivered effectively at the primary care
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teams [16].
A st h en u m b e ro fp e o p l eo nt r e a t m e n tc o n t i n u e st o
grow, there will be a need to go even further in the decen-
tralization of care and develop models of chronic disease
care outside of the formal health system. Studies from
Uganda [24], Kenya [25] and Mozambique [26] have
demonstrated that out-of-clinic approaches to ART man-
agement for stable patients are feasible, and this approach
will become increasingly important in the future as a strat-
egy to decongest overburdened health services and
simplify treatment delivery.
Improving quality of care
In the initial years of ART provision, HIV/AIDS was con-
sidered a humanitarian emergency, requiring a simple,
rapid emergency response to reduce mortality as quickly
as possible [27]. In order to provide effective, affordable
care to the millions in need, adaptations to the Western
model of care were required to simplify treatment regi-
mens and adjust delivery models to the realities of
resource-limited settings [28]. The need to continue to
increase access to treatment for those not receiving it is
still an urgent international priority. Recent evidence has
also highlighted the need to treat people at an earlier stage
during the course of their disease.
Data from European cohorts indicate that starting ART
earlier (at CD4 350 cells/mm
3 or earlier) results in signifi-
cant survival gains [29]; other cohort analyses from the
USA also showed a survival gain by treating even earlier,
at 500 CD4 cells/mm
3 [30]. The deleterious role of
chronic, ongoing HIV replication is becoming clearer -
and thus the risk of non-AIDS related complications such
as cardiovascular diseases and non AIDS-defining cancers
is a major contributor of the morbidity in HIV-infected
individuals [31]. As a result, US, French, and European
guidelines have recently been revised and recognize that
treatment can be initiated as early as below 500 CD4 cells/
mm
3, especially in patients with other co-morbidities, aged
over 50, or with organ dysfunction [32].
In line with this evidence, WHO revised its treatment
guidelines for resource-limited settings at the end of 2009,
recommending a move towards initiation at 350 cells/
mm
3 [33] (previous WHO guidelines recommended treat-
ing patients at CD4 < 200 CD4 cells/mm
3). However,
treating earlier increases the number of people eligible for
treatment, and donors and countries are still reluctant to
support this policy shift.
Another challenge has been to ensure access to some of
the newer drugs with better efficacy and side-effect pro-
files that are brought to market. The standard treatment
regimen in developing countries has relied on stavudine, a
drug that is relatively cheap (currently available as a com-
bination costing less than US$60 per person per year),
availability as a fixed-dose combination, good early toler-
ability, and its safety for use in pregnant women [11].
H o w e v e r ,t h eh i g h e rr a t eo fm itochondrial damage and
toxicity associated with stavudine that have led its use to
be progressively abandoned in developed countries [34]. In
2009, WHO revised its guidelines to recommend a move
away from stavudine towards more drugs with a better
safety profile, including tenofovir, which is also available as
a once-daily regimen [35]. The relatively higher cost of this
regimen has limited its inclusion in national protocols.
Renewed advocacy efforts are needed to ensure that the
price of tenofovir and companion drugs such as efavirenz
comes down, that sufficient tenofovir production can be
secured, and that promising new drugs in the development
pipeline are made accessible at an affordable price as soon
as they become available.
Challenges for the next phase of antretroviral
delivery
Ten years ago, global inaction against HIV/AIDS was
labelled as a crime against humanity [2]. A growing inter-
national movement fought against the high cost of treat-
ment and in just a few years succeeded in reducing the
price of ART to a fraction of its original price [7]. Small
pilot programmes that carefully selected a few dozen
patients for treatment were rapidly swept away by demand
and rapidly evolved into district wide programmes treating
thousands of patients [36]. Treatment outcomes were eval-
uated and found to be as good as those reported in
Western settings [37]. The model of ART care was
adapted from a resource-intensive individualized approach
to a public health programme that could be delivered by
nurses at the clinic and community level [15]. Contrary to
early fears, ART delivery was, after careful analysis, found
to be supportive of health system strengthening [38].
As coverage of antiretroviral therapy increased, so the
broader benefits of ART became apparent. In Malawi,
adult mortality within the general population fell by a
third as ART access increased [39], and similar declines
in mortality have been reported elsewhere [40]. There is
also emerging evidence to suggest that increased ART
coverage may have an impact on prevention by reducing
the population level viral load and thereby reducing the
overall risk of transmission [41]. Models suggest that
widespread ART coverage will result in a level of virolo-
gical suppression at the population level that will reduce
[42] or even eliminate [43] HIV transmission, and clinical
trials have recently reported significant reductions in
HIV incidence associated with earlier initiation of ART
[44]. The preventive effect of antiretroviral therapy is
currently greater than for other biomedical interventions
such as microbicides [45], vaccines [46] or pre-exposure
prophylaxis [47] to prevent HIV transmission through
sexual contacts.
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lenge. In order to ensure sustained delivery of ART to
increasing numbers and realize the potential preventive
benefits of widespread treatment coverage, efforts are
needed to reinforce the treatment cascade all along the
pathway from HIV testing to early initiation to lifelong
adherence to treatment. Recent reports indicate substan-
tial rates of attrition at each step along the care pathway
[48]. An important challenge for the next phase of ART
scale up, therefore, is to identify and implement inter-
ventions to improve uptake and retention.
Despite these major advances, there is a sense that
many of the important lessons of the past decade are
being forgotten. In 2010, the high cost of treatment was
again cited as a reason to accept sub-optimal care. The
latest WHO guidelines recommend replacing older drugs
long-abandoned in high-income countries with more
durable and less toxic alternatives, but because these
newer drugs are more expensive, developing countries
are reluctant to make the change [11]. Just as the early
benefits of ART were ignored in favour of cheaper inter-
ventions despite a clear mortality cost, this latest evi-
dence is overlooked by donors who defend a policy of
delaying treatment in order to ration resources [49]. This
is shortsighted. Given that CD4 cells deplete at approxi-
mately 90 cells per year, the savings made by delaying
initiation is around $300. But the difference in terms of
long-term survival is substantial: a patient initiating ther-
a p ya tt h ea g eo f2 0w i t haC D 4c o u n tb e l o w2 0 0h a sa n
8 year loss of life expectancy compared with initiation
above 200 cells [50].
In 2005, the international community committed to a
goal of achieving universal access to antiretroviral ther-
apy by 2010. Not only have we failed to achieve that goal,
but also the sustainability of gains made to date is under
threat from multiple sides. Clinics are reporting major
stock ruptures of antiretrovirals due in part to insuffi-
ciencies in Global Fund financing [51]. International
advisors are suggesting that treatment numbers should
s i m p l yb ef r o z e n .T h ec o n c e p to ft h e“efficiency” of drug
delivery is now the standard for programme evaluation.
A decade ago, those in the international community
who did not support the scale up of ART in Africa could
argue that it was untested. In 2011, it is now clear that
treating HIV/AIDS on a large scale is entirely possible.
Improving the basic package of care can limit side-effects
and delay the need for patients to switch to more expen-
sive second or even third-line regimens, whereas treating
earlier will potentially yield massive public health benefits
in terms of reduced transmission of HIV and other
diseases.
The challenge for the next decade is to increase access
to treatment and support sustained care for those on
treatment, while at the same time ensuring that the
package of care is continuously improved such that all
patients - whether they happen to be born in the devel-
oped world or the developing world - can benefit from
the latest improvements in drug development, clinical
science, and public health.
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